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Summary
Objective:  Study  of  patients  with  stage  T1N0M0  or  T2N0M0  glottic  cancer  treated  by  exclusive
radiotherapy  and  comparison  of  the  survival  and  functional  results  of  this  series  with  those  of
the literature.
Method:  Retrospective  study  of  stage  T1N0M0  or  T2N0M0  glottic  cancers  diagnosed  between
1st January  2000  and  31st  December  2010  and  treated  by  exclusive  radiotherapy.  Evaluation  of
survival, recurrence  and  larynx  preservation  rates.
Study centres:  CLCC  Franc¸ois-Baclesse  and  CHU  de  Caen.
Patients:  Fifty-nine  patients  (53  men  and  sixwomen)  treated  for  glottic  cancer  (57  squamous
cell carcinomas,  two  verrucous  carcinomas)  comprising  51  T1N0M0  and  eight  T2N0M0  tumours.
Treatment with  exclusive  radiotherapy  (mean  dose  of  70  Grays  limited  to  the  thyroid  cartilage
for 57  patients,  with  lymph  node  irradiation  for  two  patients).
Results:  In  this  series,  ﬁve  (9.8%)  patients  with  stage  T1N0M0  glottic  cancer  and  three  patients
(37.5%) with  stage  T2N0M0  glottic  cancer  relapsed,  corresponding  to  a  global  recurrence  rate
of 13.6%.  Three  of  the  eight  recurrences  involved  lymph  nodes  exclusively  (N),  two  patients
relapsed exclusively  at  the  primary  tumour  site  (T)  and  three  patients  presented  local  and  lymph
node recurrence  (T  and  N).  Treatment  consisted  of  salvage  total  laryngectomy  with  bilateral
cervical lymph  node  dissection  in  three  cases,  bilateral  cervical  lymph  node  dissection  and
sensitized radiotherapy  in  two  cases,  exclusive  chemotherapy  in  one  case,  cervical  lymph  node
otherapy  in  one  case.  The  last  patient  with  recurrence  died  prior  todissection  and  cervical  radi
salvage therapy.  The  larynx  preservation  rate  was  94.9%.
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Conclusion:  In  comparison  with  the  literature,  treatment  of  stage  T1-T2N0M0  glottic  cancer  by
exclusive radiotherapy  gives  very  good  results,  with  a  larynx  preservation  rate  of  95%.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Table  1  Patient  characteristics.
Patient  characteristics Numbers  Percentages
Gender
Men  53  89.8
Women 6  10.2
Age
≤ 65  years  21  35.6
> 65  years  38  64.4
WHO score
0—1 57  96.6
2 2  3.4
Lifestyle
Smoking  30  50.8
Heavy drinking  +  smoking  21  35.6
Neither  8  13.6
g
f
mated.
Table  2  Tumour-related  criteria.
Tumour  characteristics  Numbers  Percentages
Histology
Verrucous  carcinoma  2  3.4
Squamous  cell  carcinoma  57  96.6
Tumour  grade
Poorly  differentiated  2  3.4
Moderately  well  differentiated  5  8.5
Well differentiated  50  84.7
Verrucous  carcinoma  2  3.4
TNM stage
T1N0M0  51  86.4
T2N0M0  8  13.6
Purely glottic  lesion
T1aN0M0  29  49.1
T1bN0M0  18  30.5
T2N0M0  6  10.2
Supraglottic  lesionntroduction
ue  to  the  early  onset  of  symptoms,  glottic  cancers  are
iagnosed  at  stage  T1-T2N0M0  more  often  than  other  upper
erodigestive  tract  tumours.  They  represent  2%  of  all  glottic
ancers  [1].
Treatment  of  these  cancers  was  based,  for  a  long  time,
n  open  partial  laryngectomy,  and  since  the  beginning  of  the
wentieth  century,  radiotherapy.  Recent  progress  in  radio-
herapy  techniques  has  allowed  better  deﬁnition  of  target
olumes  and  preservation  of  a  maximum  of  adjacent  healthy
issues.  Endoscopic  laser  surgery  also  constitutes  a  very  good
lternative  to  these  two  techniques.
This  retrospective  study  was  designed  to  demonstrate
isk  factors  for  recurrence  of  glottic  cancer  diagnosed
t  an  early  stage  and  treated  by  exclusive  radiothe-
apy.
aterials and methods
opulation
he  CHU  de  Caen  Head  and  Neck  Department  and  the  Centre
e  Lutte  Contre  le  Cancer  (CLCC)  Franc¸ois-Baclesse  cancer
egistry  and  the  Centre  Franc¸ois-Baclesse  Radiotherapy  unit
ere  asked  to  provide  the  medical  charts  of  patients  with
tage  T1N0M0  or  T2N0M0  glottic  cancer.
Eligible  patients  presented  stage  T1  or  T2,  N0,  M0  glot-
ic  cancer  diagnosed  between  1st  January  2000  and  31st
ecember  2010,  with  no  history  of  head  and  neck  cancer
r  recurrence,  or  epidemiologically  related  cancer  (lung,
esophagus),  who  received  ﬁrst-line  treatment  by  non-
ensitized  exclusive  radiotherapy  delivered  by  two  anterior
blique  ﬁelds  and  an  anterior  ﬁeld  using  a  4  MeV  photon
eam.  No  other  treatment  (surgery,  chemotherapy)  had
een  delivered  previously.
The  risk  factors  for  recurrence  studied  were  population-
elated  (Table  1)  (age  at  diagnosis,  gender,  WHO  perfor-
ance  status),  nutritional  status  (weight,  height,  weight
oss,  body  mass  index  [BMI],  compliance  with  diet  and  nutri-
ional  supplements),  lifestyle  (heavy  drinking  and  smoking),
umour-related  criteria  (Table  2)  (TNM  stage,  supraglot-
ic/subglottic  tumour  site,  presence  of  absence  of  anterior
ommissure  involvement,  tumour  grade  (poorly,  moder-
tely  or  well  differentiated),  keratinizing  or  nonkeratinizing
ature  of  the  tumour),  as  well  as  dosimetric  criteria
dose  received  in  Grays,  volume  irradiated  and  irradiation
echnique).  The  following  criteria  were  also  recorded  for
atients  with  recurrence:  site,  time  to  onset  after  initial
iagnosis,  and  salvage  therapy.  Post-radiotherapy  functional
riteria  (swallowing  disorder,  presence  of  a  tracheotomy,
ysphonia,  dyspnoea,  presence  of  enteral  nutrition)  were
lso  recorded.As  exclusive  radiotherapy  for  stage  T1-T2N0M0
lottic  cancer  is  delivered  over  35  sessions  in  2  Gy
ractions,  the  cost  of  treatment  was  also  esti-T1N0M0  4  6.8
T2N0M0  2  3.4
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Data  analysis
The  results  of  descriptive  data  analysis  were  expressed  as
frequencies  and  exact  95%  conﬁdence  intervals  for  qualita-
tive  variables,  and  mean,  standard  deviation,  median  and
quartiles  for  quantitative  variables.
Univariate  analysis  was  performed  with  nonparametric
tests  (Fisher’s  exact  test  or  Wilcoxon’s  test  according  to  the
type  of  variable).  A  difference  between  two  variables  was
considered  to  be  signiﬁcant  for  P  <  0.05.
Overall  and  recurrence-free  survivals  were  studied  by
Kaplan-Meier  survival  curves  for  the  overall  population  and
then  as  a  function  of  the  type  of  tumour  (pure  glottic
lesions/supraglottic/subglottic  lesions).
Statistical  analysis  was  performed  with  Stata  software
(version  10).
Results
Among  250  patients  on  the  registry  and  treated  for  head  and
neck  cancer  between  1st  January  2000  and  31st  December
2010,  only  59  patients  satisﬁed  the  eligibility  criteria.  This
population  (Table  1)  comprised  53  men  and  six  women  with  a
mean  age  of  69  years  [range:  46  to  92  years].  Eight  patients
had  no  history  of  heavy  drinking  and  smoking,  30  were  only
smokers  and  21  reported  both  heavy  drinking  and  smoking.
This  series  comprised  57  squamous  cell  carcinomas  and
two  verrucous  carcinomas  with  51  stage  T1N0M0  and  eight
stage  T2N0M0  tumours;  53  patients  had  a  purely  glot-
tic  tumour  (29  T1aN0M0,  18  T1bN0M0,  six  T2N0M0)  and
six  patients  had  a  supraglottic  tumour  (four  T1N0M0,  two
T2N0M0)  (Table  2).
Fifty-seven  (96.6%)  of  the  59  patients  had  received  exclu-
sive  irradiation  to  a  dose  of  70  Grays  in  35  sessions  of  2  Grays
exclusively  to  the  tumour  site)  (Fig.  1)  and  two  patients
(3.4%)  (one  T1N0M0  supraglottic  tumour  and  one  T2N0M0
glottic  tumour)  received  a  dose  of  70  Grays  to  the  tumour
site  and  50  Grays  to  the  supraclavicular  lymph  nodes.  This
radiotherapy  was  performed  continuously  for  58  patients
and  treatment  was  suspended  for  1  week  in  one  patient  at
the  dose  of  14  Grays  out  of  70  Grays  because  of  intercurrent
illness  (not  explicitly  documented);  treatment  was  subse-
quently  resumed  on  D8  and  this  patient  received  a  total  dose
of  70  Grays.  All  patients  (except  for  one  refusal)  attended
regular  dietary  follow-up  visits  from  initiation  of  treatment
with  regular  weighing  and  dietary  advice.  A  high-calorie
nutritional  supplement  was  prescribed  during  irradiation  for
six  patients  (10.2%)  and  only  one  (1.7%)  of  these  patients
received  enteral  nutrition  by  nasogastric  tube.  Enteral  nutri-
tion  by  gastrostomy  was  never  required.
Overall  survival  —  tumour  recurrence
Eleven  of  the  59  patients  included  in  this  study  died  before
October  2011  (18.6%).  Nine  patients  died  from  non-cancer-
related  causes.  Two  (0.03%)  of  the  11  deceased  patients
presented  a  tumour  recurrence  (one  patient  died  less  than
one  month  after  salvage  total  laryngectomy  with  bilateral
cervical  lymph  node  dissection,  and  the  other  patient  died
before  salvage  therapy).
s
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Eight  patients  (13.6%)  experienced  tumour  recurrence:
ve  patients  with  stage  T1N0M0  glottic  cancer  and  three
atients  with  stage  T2N0M0  glottic  cancer.
Three  patients  presented  recurrence  conﬁned  to  the
ymph  nodes  (N)  and  were  treated  by  bilateral  jugulo-carotid
ervical  lymph  node  dissection  and  neck  radiotherapy  (two
f  these  patents  received  cisplatin-sensitized  radiotherapy).
wo  patients  relapsed  at  the  primary  tumour  site  (T):  one
as  treated  by  chemotherapy  (carboplatin-5FU)  and  the
ther  died  before  any  salvage  therapy.  Finally,  three  patients
resented  T  and  N  recurrence  and  were  treated  by  salvage
otal  laryngectomy  with  bilateral  jugulo-carotid  cervical
ymph  node  dissection.
The  larynx  preservation  rate  in  our  series  was  therefore
5%.
opulation-related  criteria
nivariate  analysis  of  patient-related  characteristics  did  not
emonstrate  any  correlation  between  recurrence  and  gen-
er  (P  =  0.49),  or  age  at  diagnosis  (P  >  0.05).
Body  mass  index  (BMI)  ranged  from  19  to  43  kg/m2 with
 mean  of  23.9  kg/m2 with  no  inﬂuence  on  the  risk  of  recur-
ence  (P  =  0.1).
ifestyle
n  this  population  of  59  patients  with  stage  T1  or  T2N0M0
lottic  cancer,  eight  patients  had  no  history  of  smoking
r  heavy  drinking,  30  were  smokers,  and  21  were  neither
rinkers  nor  smokers.  None  of  the  non-smoking,  non-drinking
atients  reported  a  history  of  gastro-oesophageal  reﬂux.  No
orrelation  was  observed  between  smoking  and/or  heavy
rinking  and  recurrence  of  glottic  cancer  after  treatment  by
xclusive  radiotherapy  (P  =  0.8).  Twenty-ﬁve  patients  (49%)
ontinued  to  smoke  or  drink  after  radiotherapy.
umour-related  criteria
ifty-seven  of  the  59  patients  included  on  this  study  had
quamous  cell  carcinoma  and  two  had  verrucous  carcinoma.
o  correlation  was  observed  between  recurrence  and  the
eratinizing  nature  of  the  tumour  (P  =  0.6)  or  the  degree  of
umour  differentiation  (P  =  0.61).
Inversely,  TNM  stage  was  positively  associated  with  the
isk  of  recurrence  (P  =  0.03),  as  a  higher  T  stage  was  associ-
ted  with  a  higher  risk  of  recurrence  of  early  glottic  cancer
reated  by  exclusive  radiotherapy.
On  Kaplan-Meier  survival  analysis,  recurrence-free  sur-
ival  appeared  to  be  better  in  patients  with  a  purely  glottic
umour  than  in  patients  with  supraglottic  or  subglottic
umour,  but  statistical  analysis  was  not  performed  because
f  the  small  number  of  patients  with  supraglottic/subglottic
umour  (Fig.  2A).
Analysis  of  the  horizontal  tumour  site  (anterior  commis-
ure  involvement  versus  tumours  without  anterior  commis-
ure  involvement)  also  showed  a trend  towards  a  higher
ecurrence  rate  for  tumours  with  anterior  commissure
nvolvement  (T  >  T1b)  (Fig.  2B).
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nalysis  of  the  functional  results  of  treatment  of  early  glot-
ic  tumours  by  exclusive  radiotherapy  at  the  dose  of  70  Grays
howed  that  20.3%  of  patients  reported  swallowing  disorders
t  the  3-month  follow-up  visit  after  completion  of  radio-
herapy.  The  various  symptoms  reported  were  hyposialia
11.9%)  or  asialia  for  one  patient  (1.7%)  who  had  received
lobal  neck  irradiation,  salivary  stasis  (1.7%),  and  dysphagia
5%).  Twenty-one  patients  (35.6%)  reported  mild  to  severe
ysphonia  at  the  3-month  follow-up  visit  after  completion  of
adiotherapy,  which  was  permanent  in  16.9%  of  cases.  Four
atients  (6%)  experienced  dyspnoea:  three  of  them  required
N
a
igure  2  Recurrence-free  survival.  A.  Comparison  of  recurrence-fr
lottic tumours.  B.  Comparison  of  recurrence-free  survivals  betweeneal  irradiation  dosimetry.
racheotomy  and  one  patient  described  breathlessness  on
xertion.
Three  patients  with  tumour  recurrence  required  tra-
heotomy  during  the  weeks  following  radiotherapy.  One
atient  with  a  stage  T1bN0M0  glottic  cancer  developed  T
ecurrence  and  required  tracheotomy  6  months  after  the
tart  of  treatment.  One  patient  initially  presenting  a  stage
1N0M0  supraglottic  carcinoma  developed  exclusively  N
ecurrence  and  was  treated  by  tracheotomy  for  laryngeal
edema  2  years  and  1  month  after  radiotherapy.  One  patient
ith  stage  T2N0M0  supraglottic  carcinoma  developed  T  and recurrence  and  required  emergency  tracheotomy  2  years
nd  3  months  after  starting  radiotherapy.  The  recurrence
ee  survival  between  supraglottic/subglottic  tumours  and  purely
 stage  T1a  and  stage  T1b  and  T2  glottic  cancers.
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Table  3  Cost  of  treatment.
Procedures  (Elekta  apparatus)  Number  of  sessions  Cost  per  session  (D)  Total  (D)
Treatment  planning  and  dosimetry  1  1004.30  1004.30
Irradiation session  35  84.48  2956.80
Total —  —  3961.10
Table  4  Five-year  local  control  rate  of  patients  with  stage  T1N0M0  or  T2N0M0  glottic  cancer  treated  by  exclusive  external
radiotherapy.
References Number  of  patients T1a  (%) T1b  (%) T2a  (%) T2b  (%)
Chera  et  al.,  2010  [2] 585  94  93  80  70
Groome et  al.,  2006  [3]  704  82  82  63  63
Frata et  al.,  2005  [4]  256  —  —  73  73
Garden et  al.,  2003  [5]  230  —  —  74  70
Warde et  al.,  1998  [6]  735  91  82  69  69
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rate  appeared  to  be  higher  among  patients  treated  by  tra-
cheotomy  (P  =  0.002).
Cost  of  treatment
The  mean  cost  of  treatment,  without  taking  into  account
transport  and  hospitalisation  costs,  was  estimated  to  be
D  3961.10  (Table  3).
Discussion
The  treatment  of  stage  T1N0M0  or  T2N0M0  glottic  cancer
is  based  on  various  techniques.  The  results  of  the  present
series  are  similar  to  those  reported  the  literature  with  a
global  recurrence  rate  of  13.6%  and  a  larynx  preservation
rate  of  95%.
Depending  on  the  author,  the  global  recurrence  rate
ranges  from  8%  to  20.75%  for  patients  treated  by  external
radiotherapy  at  the  dose  of  70  Grays  (Table  4) [2—7],  0%  to  9%
for  those  treated  with  endoscopic  laryngeal  surgery  [8]  and
about  11%  for  those  treated  by  open  partial  laryngectomy
[9].
The  larynx  preservation  rate  ranges  from  73  to  95%  after
external  radiotherapy  at  the  dose  of  70  Grays,  [4,10],  and
91  to  100%  after  endoscopic  surgery  and  open  surgery  [8,9].
According  to  Spector  et  al.,  local  disease  control,
remission,  survival  and  larynx  preservation  rates  are  not  sta-
tistically  different  (P  =  0.89)  between  patients  with  stage
T1-T2N0M0  glottic  cancer  treated  by  partial  laryngectomy
and  those  treated  by  external  radiotherapy  at  a  dose  of
70  Grays  [9].  The  survival  rate  for  patients  with  stage
T1N0M0  glottic  cancer  is  not  signiﬁcantly  different  (P  =  0.68)
between  the  four  treatment  techniques  (58  Gy  radiotherapy
[55—65  Gy],  high-dose  radiotherapy  [65—70  Gy],  open  par-
tial  laryngectomy,  and  endoscopic  surgery)  [11]. In  this  same
study,  the  larynx  preservation  rate  was  similar  for  patients
treated  by  70  Gy  radiotherapy  (89%),  open  partial  laryngec-
tomy  (93%)  and  endoscopic  surgery  (90%),  but  the  larynx
D
T
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reservation  rate  was  signiﬁcantly  lower  for  patients  treated
y  58  Gy  radiotherapy  (80%,  P  =  0.02)  [11].
Multivariate  analysis  [12]  based  on  522  patients  with  early
tage  glottic  cancer  treated  by  radiotherapy  showed  a  local
ontrol  rate  of  87.5%  for  Tis,  94.7%  for  T1  and  84.5%  for
2.  Absence  of  anterior  commissure  involvement  [7,13—15],
reserved  laryngeal  mobility  and  an  irradiation  dose  greater
han  60  Gy  [12]  appeared  to  be  positive  predictive  factors
or  local  disease  control.  Univariate  analysis  showed  that
ngoing  smoking,  diabetes,  tumour  stage  and  involvement  of
ore  than  one-third  of  the  vocal  cord  were  correlated  with
oor  local  disease  control  (P  =  0.027)  [16].  Absence  of  ante-
ior  commissure  and  ventricle  involvement  and  preserved
aryngeal  mobility  were  signiﬁcant  survival  prognostic  fac-
ors  [17].
onclusion
he  treatment  of  stage  T1-T2N0M0  glottic  cancer  by  exclu-
ive  external  radiotherapy  at  the  dose  of  70  Grays  (2  Grays
er  day)  remains  a  good  alternative  to  surgery.  This
echnique  is  essentially  indicated  in  patients  with  major
omorbidity  or  who  refuse  surgery.  The  overall  survival
ate  and  larynx  preservation  rate  do  not  vary  signiﬁ-
antly  according  to  the  type  of  treatment  (radiotherapy  or
urgery).
Anterior  commissure  involvement  and  tumour  stage
ppear  to  be  correlated  with  a  higher  recurrence  rate.  The
est  results  are  obtained  for  stage  T1N0M0  glottic  cancer
ithout  supraglottic/subglottic  extension.
Larynx  preservation  remains  the  major  determinant  in
he  choice  of  treatment.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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